ATE158180T1 - Oral verabreichbare therapeutische proteine und herstellungsverfahren - Google Patents

Oral verabreichbare therapeutische proteine und herstellungsverfahren

Info

Publication number
ATE158180T1
ATE158180T1 AT92914240T AT92914240T ATE158180T1 AT E158180 T1 ATE158180 T1 AT E158180T1 AT 92914240 T AT92914240 T AT 92914240T AT 92914240 T AT92914240 T AT 92914240T AT E158180 T1 ATE158180 T1 AT E158180T1
Authority
AT
Austria
Prior art keywords
protein
orally administered
therapeutic protein
production methods
therapeutic proteins
Prior art date
Application number
AT92914240T
Other languages
English (en)
Inventor
Jacob G Michael
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Application granted granted Critical
Publication of ATE158180T1 publication Critical patent/ATE158180T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92914240T 1991-06-21 1992-06-11 Oral verabreichbare therapeutische proteine und herstellungsverfahren ATE158180T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71916091A 1991-06-21 1991-06-21

Publications (1)

Publication Number Publication Date
ATE158180T1 true ATE158180T1 (de) 1997-10-15

Family

ID=24888975

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92914240T ATE158180T1 (de) 1991-06-21 1992-06-11 Oral verabreichbare therapeutische proteine und herstellungsverfahren

Country Status (11)

Country Link
US (4) US5609871A (de)
EP (1) EP0590060B1 (de)
JP (1) JPH06508371A (de)
AT (1) ATE158180T1 (de)
AU (1) AU664561B2 (de)
CA (1) CA2110899C (de)
DE (1) DE69222306T2 (de)
DK (1) DK0590060T3 (de)
ES (1) ES2109362T3 (de)
GR (1) GR3025628T3 (de)
WO (1) WO1993000077A1 (de)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508371A (ja) * 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
DE69305313T3 (de) † 1992-12-22 2001-06-21 The University Of Cincinnati, Cincinnati Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5551058A (en) * 1994-10-31 1996-08-27 Motorola, Inc. Method and system for intelligent cell selection using location data in cellular systems
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US6605276B1 (en) * 1995-05-09 2003-08-12 University Of Medicine & Dentistry Of New Jersey Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms
US5789014A (en) * 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
JP2000509146A (ja) * 1996-04-12 2000-07-18 オンコール，インコーポレーテッド 遅延クエンチングによりホルムアルデヒド固定を制御する方法および組成物
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
DE19854749A1 (de) * 1998-11-27 2000-05-31 Privates Inst Bioserv Gmbh Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen
CN1193791C (zh) * 1998-11-30 2005-03-23 希托斯生物技术股份公司 抗原的有序分子呈递,制备及使用的方法
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
WO2001017536A2 (de) * 1999-09-07 2001-03-15 Bioserv Ag Neue autovakzinen zur erzielung einer immuntoleranz
US6500462B1 (en) * 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
EP1244468A2 (de) * 2000-01-07 2002-10-02 University Of Cincinnati Selektive aktivierung einer th1 oder th2 lymphozyten regulierten immunantwort
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP1586329A1 (de) * 2000-02-08 2005-10-19 Allergan, Inc. Pharmazeutische Zusammensetzungen mit botulinum Toxin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
AU2002213843B2 (en) 2000-11-10 2008-02-07 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
TR200300731T2 (tr) 2000-11-28 2004-08-23 Fmc Corporation Yenebilir PGA kaplama bileşimi
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US20060040899A1 (en) * 2000-12-15 2006-02-23 Hassan Jomaa Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
WO2003028668A2 (en) * 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US20030091637A1 (en) * 2001-10-15 2003-05-15 Hans-Ulrich Petereit Use of a copolymer to prepare a pharmaceutical form that contains a peptide of protein as active principle
CN100467060C (zh) 2002-05-10 2009-03-11 阿根尼克斯有限公司 通过瘤内施用乳铁蛋白治疗恶性肿瘤疾病的用途
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US7977098B2 (en) 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
EP1532279B1 (de) * 2002-05-31 2011-02-16 Children's Hospital Medical Center Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
JP4516844B2 (ja) 2002-09-16 2010-08-04 エイジェニックス インコーポレイテッド 創傷の処置におけるラクトフェリン
MXPA05003884A (es) 2002-10-16 2005-10-05 Euro Celtique Sa Anticuerpos que enlazan polipeptidos ca 125/0772p a celulas asociadas y metodos de uso de los mismos.
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558647B1 (de) 2002-11-08 2015-06-10 Ablynx N.V. Einzeldomaene antikörpern gegen tnf-alpha und ihre verwendungen
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
BRPI0409128A (pt) * 2003-04-08 2006-03-28 Progenics Pharm Inc uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
ES2528669T3 (es) * 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
EP2591786B1 (de) 2003-10-16 2017-04-12 Cancure Limited Immunmodulierende Zusammensetzungen und ihre Verwendung
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
CN101043891A (zh) 2004-09-18 2007-09-26 巴尔的摩马里兰大学 靶向NCCa－ATP通道的治疗剂及其使用方法
AU2005293752A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
BRPI0606587A2 (pt) * 2005-01-20 2009-07-07 Progenics Pharmaceuticais Inc uso de metilnaltrexona e compostos correlatos para tratar disfunção gastrintestinal pós-operatória
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
CA2605652C (en) 2005-04-22 2016-05-24 Universite De Geneve Polylactide compositions and uses thereof
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
CA2655331A1 (en) 2006-06-22 2007-12-27 Agennix Incorporated Lactoferrin as a radioprotective agent
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20110152263A1 (en) * 2006-11-16 2011-06-23 Xi Jiang Composition and method for inhibiting norovirus infection
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
AU2008214095B2 (en) 2007-02-02 2014-07-10 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
PL2139890T3 (pl) * 2007-03-29 2014-11-28 Wyeth Llc Antagoniści obwodowych receptorów opioidowych i ich zastosowania
BRPI0809579B8 (pt) 2007-03-29 2021-05-25 Progenics Pharm Inc formas cristalinas e seus usos
PE20090700A1 (es) * 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
MX367012B (es) 2007-06-01 2019-08-02 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
EP2167107B1 (de) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitoren von ncca-atp-kanälen zur therapie
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2009265034B2 (en) 2008-07-01 2015-09-03 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
EP2326318A4 (de) 2008-09-16 2012-05-23 Univ Maryland Sur1-hemmer für therapeutische zwecke
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
ES2702049T3 (es) 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
US8486421B2 (en) 2009-06-09 2013-07-16 Children's Hospital Medical Center Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods for their making and use
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
WO2011104352A1 (en) 2010-02-25 2011-09-01 Agennix Ag Oral lactoferrin in the treatment of severe sepsis
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
EP3636778B1 (de) 2010-08-18 2022-01-12 Fred Hutchinson Cancer Research Center Verfahren zur bestimmung des vorhandenseins oder risikos der entwicklung fazioskapulohumeraler muskeldystrophie (fshd)
MX354016B (es) 2010-09-15 2018-02-07 J Mrsny Randall Sistemas y metodos de suministro de agentes bioactivos mediante el uso de secuencias transportadoras derivadas de toxinas.
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP5911874B2 (ja) 2010-10-18 2016-04-27 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 発毛を促進又は増強するためのエキソソームの使用
WO2012070971A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Косметологическая и фармацевтическая композиция для омоложения и восстанов- ления кожи, в том числе после хирургических операций
ES2751388T3 (es) 2011-07-22 2020-03-31 Univ Chicago IGF-1 para su uso en el tratamiento de la jaqueca
WO2013057592A2 (en) 2011-09-14 2013-04-25 King Abdullah University Of Science And Technology Treatment of sickle cell disease
US9644005B2 (en) 2011-09-21 2017-05-09 King Abdullah University Of Science And Technology Didemnin biosynthetic gene cluster in Tistrella mobilis
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
WO2014160339A1 (en) 2013-03-13 2014-10-02 Board Of Regents, The University Of Texas System Compounds for treating inflammatory and hyperproliferative diseases
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
NZ720311A (en) 2013-12-02 2022-10-28 Baylor College Medicine Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
EA033248B1 (ru) * 2014-02-20 2019-09-30 Вэксарт, Инк. Композиция и способ индукции иммунного ответа
WO2015167959A1 (en) * 2014-04-28 2015-11-05 Sigma-Aldrich Co. Llc Epigenetic modification of mammalian genomes using targeted endonucleases
EP3139965B1 (de) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Von cholixtoxin abgeleitete fusionsmoleküle zur oralen verabreichung von biologisch aktiven stoffen
US10278986B2 (en) 2014-08-14 2019-05-07 The Regents Of The University Of Colorado, A Body Corporate Antibody-siRNA conjugates and uses therefor
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
EP3206491B1 (de) 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Verwendung von methylnaltrexon zur verringerung der tumorprogression
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
KR101708200B1 (ko) 2015-03-24 2017-03-08 아우토리브 디벨롭먼트 아베 차량용 커튼 에어백
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3285792B1 (de) 2015-04-20 2020-11-04 The Board of Regents of The University of Texas System Knochenwachstumsmittel clec11a
JP6912394B2 (ja) 2015-06-12 2021-08-04 バクサート インコーポレイテッド Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤
US10962551B2 (en) 2015-06-17 2021-03-30 The Johns Hopkins University TDP-43 in degenerative disease
FI3325011T6 (fi) 2015-07-24 2023-05-11 Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi
CN117964732A (zh) 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
US10695322B2 (en) 2016-01-29 2020-06-30 The Johns Hopkins University Inhibitors of bacterial growth
US11040025B2 (en) 2016-02-17 2021-06-22 The Johns Hopkins University Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
WO2017147370A1 (en) 2016-02-24 2017-08-31 The Johns Hopkins University Novel antiviral proteins and their uses in therapeutic methods
WO2017155935A1 (en) 2016-03-07 2017-09-14 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
BR112018068055A2 (pt) 2016-03-10 2019-01-08 Univ Johns Hopkins métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas
KR102889062B1 (ko) 2016-03-17 2025-11-21 더 존스 홉킨스 유니버시티 Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
EP3436609B1 (de) 2016-03-30 2022-05-04 The Johns Hopkins University Olfr90-spezifität und nachweisverfahren
SG11201807402PA (en) 2016-03-31 2018-09-27 Vhsquared Ltd Compositions
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
MX2019000887A (es) 2016-07-22 2019-09-04 Gliknik Inc Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc.
EP3295956A1 (de) 2016-09-20 2018-03-21 Biomay Ag Polypeptidkonstrukt mit fragmenten von allergenen
US11149275B2 (en) 2016-10-10 2021-10-19 The Johns Hopkins University Device and method to treat esophageal disorders
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
KR102729723B1 (ko) 2016-12-09 2024-11-15 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
CN116003564A (zh) 2017-03-14 2023-04-25 贝勒医学院 作为Hippo效应子的显性活性Yap诱导染色质可及性和心肌细胞更新
JP7641695B2 (ja) 2017-03-28 2025-03-07 チルドレンズ ホスピタル メディカル センター ノロウイルスｓ粒子ベースのワクチンならびにその作製および使用方法
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
ES2938609T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
WO2019118527A1 (en) 2017-12-14 2019-06-20 The Johns Hopkins University Novel anti-fungal inhibitors
WO2019173478A2 (en) 2018-03-06 2019-09-12 The Johns Hopkins University Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
AU2019230230B2 (en) 2018-03-08 2025-04-10 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
KR20250174998A (ko) 2018-03-08 2025-12-15 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
CN112770735A (zh) 2018-07-29 2021-05-07 Musc研究发展基金会 用于治疗神经或线粒体疾病的化合物
WO2020033130A1 (en) 2018-08-06 2020-02-13 The Johns Hopkins University Treatment of irritable bowel syndrome with molybdenum
US12103968B2 (en) 2018-08-16 2024-10-01 The Johns Hopkins University Antibodies to human ZnT8
EP3921029B1 (de) 2019-02-07 2025-07-30 Baylor College of Medicine Ccl5 enthaltende zusammensetzung zur verwendung bei der behandlung von knochenbruch, knochenfrakturen, knochendegeneration und osteoporose
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
MX2021015761A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
BR112022008817A2 (pt) 2019-11-27 2022-07-26 Alx Oncology Inc Terapias combinadas para tratamento de câncer
CA3164937A1 (en) 2019-12-26 2021-07-01 Figene, Llc Prevention and treatment of kidney failure by administration of fibroblasts and products thereof
US20230026352A1 (en) 2019-12-26 2023-01-26 Figene, Llc Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof
AU2021230540A1 (en) 2020-03-04 2022-10-13 Pleopharma, L.L.C. Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
LU76538A1 (de) * 1977-01-07 1978-09-18
US4469677A (en) * 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5230888A (en) * 1982-05-06 1993-07-27 Massachusetts Institute Of Technology Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
SE8303401D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Beredning och dess anvendning
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0192321A3 (de) * 1985-01-19 1987-09-02 Beecham Group Plc Allergene enthaltende Arzneimittel mit magensaftresistentem Überzug
CH663900A5 (de) * 1985-05-06 1988-01-29 Cernitin Sa Pharmazeutisches praeparat zur prophylaktischen behandlung von allergien und verfahren zur herstellung dieses praeparates.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US4820627A (en) * 1986-03-24 1989-04-11 Em Diagnostic Systems, Inc. Method of preparing particles suitable for tabletting into diagnostic reagents
JPH0759496B2 (ja) * 1986-03-25 1995-06-28 ロ−ト製薬株式会社 歯周病治療剤
US5019384A (en) * 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
AU604052B2 (en) * 1986-08-28 1990-12-06 Enzacor Properties Limited Animal growth promotant
FR2609895B1 (fr) * 1987-01-28 1991-06-28 Bruttmann Georges Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
EP0279095A1 (de) * 1987-02-20 1988-08-24 Shikoku Chemicals Corporation Chemotherapeutische Zusammensetzung
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5236713A (en) * 1987-10-21 1993-08-17 Teikoku Seiyaku Kabushiki Kaisha Preparation for intermittently releasing active agent applicable to oral cavity
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
ES2042292T3 (es) * 1989-03-17 1993-12-01 Pitman-Moore, Inc. Dispositivo de administracion de proteinas macromoleculares por liberacion controlada.
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
IL99754A (en) * 1990-10-15 1996-08-04 Autoimmune Inc Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
JPH06508371A (ja) * 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
DE69305313T3 (de) * 1992-12-22 2001-06-21 The University Of Cincinnati, Cincinnati Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen

Also Published As

Publication number Publication date
JPH06508371A (ja) 1994-09-22
ES2109362T3 (es) 1998-01-16
EP0590060B1 (de) 1997-09-17
DE69222306T2 (de) 1998-04-09
DK0590060T3 (da) 1998-05-11
US5609871A (en) 1997-03-11
CA2110899A1 (en) 1993-01-07
EP0590060A1 (de) 1994-04-06
CA2110899C (en) 2006-08-08
GR3025628T3 (en) 1998-03-31
WO1993000077A1 (en) 1993-01-07
EP0590060A4 (en) 1994-05-25
DE69222306D1 (de) 1997-10-23
US5783193A (en) 1998-07-21
AU2249692A (en) 1993-01-25
AU664561B2 (en) 1995-11-23
US6174529B1 (en) 2001-01-16
US5629001A (en) 1997-05-13

Similar Documents

Publication Publication Date Title
ATE158180T1 (de) Oral verabreichbare therapeutische proteine und herstellungsverfahren
DK0603992T3 (da) Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
SE8001736L (sv) Indolerivat med terapeutisk verkan jemte sett for deras framstellning
KR870700361A (ko) 경구적 전달 방법
NO882732D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
DK0994721T3 (da) Nervevækstfaktor som vaccineadjuvans
SE8405587D0 (sv) Forfarande for mikroflorabindning
NO982904L (no) Oral farmas°ytisk sammensetning inneholdende 5-ASA, med modifisert frigj°ring, og fremgangsmÕte for behandling av tarmsykdommer
US20030215506A1 (en) Methods and compositions for enhancement of creatine transport
PT1065947E (pt) Metodo de administracao de glutamina
IE791409L (en) Galactomannan polysaccharide gum formulation containing¹gellation inhibitor
JP3854657B2 (ja) 腸管保護剤
DK0421949T3 (da) Kemisk modificerede allergener og fremgangsmåde til deres fremstilling
JPH0797332A (ja) 低血圧のリスクを減少させる組成物及び方法
RU93009804A (ru) Вакцина против эшерихиоза животных
EP1131338A4 (de) Methode für die herstellung von gereinigtem invasinprotein und seine anwendung
IE35321L (en) Treatment of pigs with bacterial endotoxins.
FR2618439B1 (fr) Sequences d'amino-acides reproduisant au moins en partie la sequence des lectines animales et humaines, leurs procedes d'obtention, leurs applications diagnostiques et therapeutiques
RU2000104571A (ru) Способ коррекции иммунной недостаточности при желудочно-кишечных заболеваниях поросят
EA200200687A1 (ru) Композиция для усиления пролиферативного ответа в процессе адаптации желудочно-кишечного тракта и применения при синдроме укороченной тонкой кишки
RU97117569A (ru) Гастроветин
JP2001342127A (ja) 腸吸収性抗炎症因子含有免疫性物質及びその応用
RU95101369A (ru) Противоязвенное средство
CN107048341A (zh) 一种酶的应用技术及其改善了消化性的药食用动物胶
RU2000126729A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee